STAGE IV BREAST CANCER AJCC V6 AND V7
Clinical trials for STAGE IV BREAST CANCER AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV BREAST CANCER AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE IV BREAST CANCER AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple threat: new drug combo aims to shrink advanced breast cancer
Disease control OngoingThis study tested whether adding an immunotherapy drug (pembrolizumab) to standard hormone therapy (letrozole or fulvestrant) and a targeted drug (palbociclib) could shrink tumors in postmenopausal women with newly diagnosed stage IV estrogen receptor positive (ER+) breast cancer…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
Could a drug combo boost Chemo's power against breast cancer?
Disease control OngoingThis early-phase trial tested the safety and best dose of combining veliparib with the chemotherapy drug carboplatin in 44 people with HER2-negative breast cancer that had spread. The goal was to see if veliparib could stop cancer cells from repairing damage caused by carboplatin…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:58 UTC
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial studies two drug combinations (olaparib plus vistusertib or olaparib plus capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The main goal is to find the safest dose and understand side effects. About 15…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New drug combo shows promise in Hard-to-Treat breast cancer
Disease control OngoingThis early-phase trial tested a combination of two drugs—low-dose cyclophosphamide and veliparib—in 35 people with HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combo could shrink tumors. While n…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New drug Z-Endoxifen takes on tamoxifen in breast cancer battle
Disease control OngoingThis study tests whether a newer drug, Z-Endoxifen, works better than the standard drug tamoxifen for postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The cancer has spread or come back despite prior hormone therapy. About 81 women will be randomly …
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New combo therapy aims to zap spine tumors before they paralyze
Disease control OngoingThis study tests whether using heat (thermal ablation) followed by very precise radiation (stereotactic radiosurgery) can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with various solid tumors (like lung, breast, or prosta…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:52 UTC
-
New drug Z-Endoxifen shows promise in early breast cancer trial
Disease control OngoingThis early-phase study tested a drug called Z-endoxifen in 62 women with a type of breast cancer that has spread or come back. The goal was to find the safest dose and see how well it blocks estrogen, which can fuel cancer growth. Participants had estrogen receptor-positive (ER+)…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for hard-to-treat cancers? drug targets tumors with unstable genes
Disease control OngoingThis study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New scan could predict which breast cancer patients will respond to hormone therapy
Diagnosis OngoingThis study is testing whether a special PET scan called FES PET/CT can predict how well hormone therapy will work for people with newly diagnosed breast cancer that has spread. The scan uses a radioactive form of estrogen to light up cancer cells that respond to hormones. About 9…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated May 26, 2026 07:24 UTC
-
New imaging method tracks breast cancer response to hormone treatment
Knowledge-focused OngoingThis trial uses a special PET scan (FES) to measure estrogen receptors in breast cancer tumors before, during, and after hormone therapy. It includes adults with estrogen receptor-positive breast cancer that is new, has returned, or spread. The goal is to see if changes in scan r…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 26, 2026 07:24 UTC